Conrad D. Oja
About
Conrad D. Oja is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology.
According to data from OpenAlex, Conrad D. Oja has authored 20 papers receiving a total of 965 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 8 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Conrad D. Oja's work include Prostate Cancer Treatment and Research (12 papers), Cancer Genomics and Diagnostics (6 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Conrad D. Oja is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Cancer Genomics and Diagnostics (6 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Conrad D. Oja collaborates with scholars based in Canada, Finland and Australia. Conrad D. Oja's co-authors include Muhammad Zulfiqar, Joanna Vergidis, Daygen L. Finch, Martin Gleave, Kim N., Daniel Khalaf, Katherine Sunderland, Bernhard J. Eigl, Alexander W. Wyatt and Matti Annala and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Lancet Oncology.
In The Last Decade
Conrad D. Oja
19 papers receiving 955 citations
Hit Papers
Peers
Conrad D. Oja
Mari Nakazawa United States
Andreas Varkaris United States
Andrea Zivi United Kingdom
Annemieke J.M. Nieuweboer Netherlands
A. Delacruz United States
Giorgia Gurioli Italy
Neelima Vidula United States
William Berry United States
R. Nevin Murray Canada
S. Falcon Peru
Citations per year, relative to Conrad D. Oja Conrad D. Oja (= 1×)
peers
Mari Nakazawa
Countries citing papers authored by Conrad D. Oja
Since
Specialization
Citations
This map shows the geographic impact of Conrad D. Oja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conrad D. Oja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conrad D. Oja more than expected).
Fields of papers citing papers by Conrad D. Oja
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Conrad D. Oja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conrad D. Oja. The network helps show where Conrad D. Oja may publish in the future.
Co-authorship network of co-authors of Conrad D. Oja
This figure shows the co-authorship network connecting the top 25 collaborators of Conrad D. Oja. A scholar is included among the top collaborators of Conrad D. Oja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conrad D. Oja. Conrad D. Oja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623.
2.
Khalaf, Daniel, Katherine Sunderland, Bernhard J. Eigl, et al.. (2020). Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.. Journal of Clinical Oncology. 38(15_suppl). 5578–5578.
3.
Aragón, Isabel M., Daniel Khalaf, Rebeca Lozano, et al.. (2020). HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.. Journal of Clinical Oncology. 38(15_suppl). 5525–5525.
4.
Khalaf, Daniel, Matti Annala, Sinja Taavitsainen, et al.. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology. 20(12). 1730–1739.
5.
Annala, Matti, Gillian Vandekerkhove, Daniel Khalaf, et al.. (2018). Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery. 8(4). 444–457.
6.
Jones, Edward C., et al.. (2018). Immune system trickery and deception: Allograft-derived neuroendocrine carcinoma post kidney transplantation. Urology Case Reports. 21. 89–91.
7.
Khalaf, Daniel, Katherine Sunderland, Bernhard J. Eigl, et al.. (2018). Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. European Urology. 75(6). 940–947.
8.
Khalaf, Daniel, Matti Annala, Daygen L. Finch, et al.. (2018). Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.. Journal of Clinical Oncology. 36(15_suppl). 5015–5015.
9.
Khalaf, Daniel, Matti Annala, Kevin Beja, et al.. (2017). Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(6_suppl). 186–186.
10.
N., Kim, Matti Annala, Katherine Sunderland, et al.. (2017). A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5002–5002.
11.
Khalaf, Daniel, Katherine Sunderland, Bernhard J. Eigl, et al.. (2017). Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5036–5036.
12.
Wyatt, Alexander W., Matti Annala, Kevin Beja, et al.. (2016). Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy. Annals of Oncology. 27. vi17–vi17.
13.
Wyatt, Alexander W., Matti Annala, Sunil Parimi, et al.. (2016). Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). 5034–5034.
14.
Parimi, Sunil, Bernhard J. Eigl, Katherine Sunderland, et al.. (2016). Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). 5059–5059.
15.
Goodwin, Pamela J., Wendy R. Parulekar, Karen A. Gelmon, et al.. (2015). Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. JNCI Journal of the National Cancer Institute. 107(3). djv006–djv006.
16.
Goodwin, Pamela J., Wendy R. Parulekar, Karen A. Gelmon, et al.. (2013). Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. Journal of Clinical Oncology. 31(15_suppl). 1033–1033.
17.
Oja, Conrad D.. (2009). Studies on Factors influencing the elimination of liposomes from the circulation. Open Collections.
18.
Wong, Frances M. P., et al.. (2002). A Lipid-based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. Journal of drug targeting. 10(8). 615–623.
19.
Oja, Conrad D., et al.. (2000). Doxorubicin entrapped within liposome-associated antigens results in a selective inhibition of the antibody response to the linked antigen. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1468(1-2). 31–40.
20.
Oja, Conrad D., Sean C. Semple, Arcadio Chonn, & Pieter R. Cullis. (1996). Influence of dose on liposome clearance: critical role of blood proteins. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1281(1). 31–37.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mari Nakazawa Breakdown of academic impact, for papers by Andreas Varkaris Breakdown of academic impact, for papers by Andrea Zivi Breakdown of academic impact, for papers by Annemieke J.M. Nieuweboer Breakdown of academic impact, for papers by A. Delacruz Breakdown of academic impact, for papers by Giorgia Gurioli Breakdown of academic impact, for papers by Neelima Vidula Breakdown of academic impact, for papers by William Berry Breakdown of academic impact, for papers by R. Nevin Murray Breakdown of academic impact, for papers by S. Falcon